The myNEO ImmunoEngine neoantigen prediction platform incorporates years of development ensuring confident identification of as many antigens as possible. The variety of filters/ranking mechanisms based on biological processes retain the neoantigen targets providing the most clinical benefit in terms of response strength, duration (memory induction), breadth, and overall survival.
The advanced features are divided amongst three modules, as per their purpose:
- Tumour-specific variant: to identify all the tumour-specific alterations with high confidence based on the sequencing data of the tumour
- Tumour-specific surface peptide: to predict which of the identified alterations will lead to changes in the presented antigen repertoire on the surface of the tumour cells.
- Immunogenicity response: to evaluate the immunogenic impact of a therapy against the selected peptides